Claims for Patent: 10,004,694

Summary for Patent: 10,004,694

Title:	Targeted poorly water-soluble drug delivery system, method of preparing the same, and pharmaceutical composition including the same
Abstract:	Provided are a poorly water-soluble drug delivery system, a method of preparing the same, a method of delivering a poorly water-soluble drug using the same, and a pharmaceutical composition including the same as an effective component, and more particularly, a poorly water-soluble drug delivery system aiming cancer cell specific targeting, which may variously control the kind of a cancer cell targeting material capable of specifically reacting to an antigen overexpressed in a cancer cell, thereby binding to the surface of the poorly water-soluble drug delivery system, and variously control the kind of a poorly water-soluble drug encapsulated therein depending on the kind of cancer and a therapeutic purpose, thereby being effectively applicable to a cancer treatment method.
Inventor(s):	Park; Keunchil (Seoul, KR), Kim; Jin-Ho (Icheon, KR), Kim; Youngwook (Seongnam, KR), Bae; Ki Hyun (Bukit Batok, SG)
Assignee:	SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR)
Application Number:	14/427,361
Patent Claims:	1. A targeting poorly water-soluble drug delivery system comprising: a solid nanoparticle comprising a core lipid part containing cholesteryl ester and triglyceride, and a surface lipid part containing phospholipid, cholesterol and cationic lipid, a poorly water-soluble drug encapsulated in the solid nanoparticle, and a targeting material connected to the surface lipid part by a polymer linker, wherein the polymer linker is represented by chemical formula 1: ##STR00002## where R is the cationic lipid of the surface lipid part; where R' is the targeting material; where n is an integer of 4 to 1130; and where the drug delivery system improves apoptosis efficiency relative to a solid nanoparticle comprising the poorly water-soluble drug alone. 2. The drug delivery system of a poorly water-soluble drug according to claim 1, wherein the drug delivery system comprises 30 to 60 wt % of cholesteryl ester; 0.1 to 10 wt % of triglyceride; 5 to 30 wt % of phospholipid; 5 to 20 wt % of cholesterol; cationic lipid 10 to 50 wt % of; and 10 to 20 wt % of the poorly water-soluble drug. 3. The drug delivery system of a poorly water-soluble drug according to claim 1, wherein the cholesteryl ester is an ester compound of an unsaturated fatty acid having a carbon number of 10 to 24, and cholesterol. 4. The drug delivery system of a poorly water-soluble drug according to claim 1, wherein the triglyceride is at least one selected from the group consisting of triacetin, tributyrin, tricaproin, tricaprylin, tricaprin and triolein. 5. The drug delivery system of a poorly water-soluble drug according to claim 1, wherein the phospholipid is at least one selected from the group consisting of dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), egg phosphatidylcholine (EPC), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG) and dipalmitoylphosphatidylglycerol (DPPG). 6. The drug delivery system of a poorly water-soluble drug according to claim 1, wherein the cationic lipid is at least one selected from the group consisting of 3beta-[N--(N',N',N'-trimethylaminoethan)carbamoyl]cholesterol (TC-cholesterol), 3beta[N--(N',N'-dimethylaminoethane)carbamoyl]cholesterol (DC-cholesterol), 3beta[N--(N'-monomethylaminoethane)carbamoyl]cholesterol (MC-cholesterol), 3beta[N-(aminoethane)carbamoyl]cholesterol (AC-cholesterol), N--(N'-aminoethane)carbamoylpropanoictocoperol (AC-tocoperol), N--(N'-methylaminoethane) carbamoylpropanoictocoperol (MC-tocoperol), N,N-dioleyl-N,N-dimethylammonium chloride(DODAC), N,N-disterayl-N,N-dimethylammonium bromide (DDAB), N-(1-(2,3-dioleoyloxy)propyl-N,N,N-trimethylammonium chloride (DOTAP), N,N-dimethyl-(2,3-dioleoyloxy)propylamine (DODMA), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), 1,2-dioleoylcarbamyl-3-dimethylammonium-propane (DOCDAP), 1,2-dilinoyl-3-dimethylammonium-propane (DLINDAP), dioleoyloxy-N-[2-sperminecarboxamido)ethyl}-N,N-dimethyl-1-propane aminium trifluoro-acetate (DOSPA), dioctadecyl-amidoglycylspermine (DOGS), 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethylammoniumbromide (DMRIE), 3-dimethylamino-2-(chlest-5-en-3-beta-oxybutane-4-oxy)-1-(cis,ci- s-9, 12-oc- tadicadienoxy) propane (CLinDMA), 2-[5'-(cholest-5-ene-3beta-oxy)-3'-oxapentoxy)-3-dimethyl-1-(cis,cis-9', 1-2'-octadicardienoxy)propane (CpLinDMA), N,N-dimethyl-3,4-dioleoyloxybenzylamine (DMOBA), 1,2-N,N'-dioleylcarbamyl-3-dimethylaminopropane (DOcarbDAP), 1,2-diacyl-3-trimethylammonium-propane (TAP) and 1,2-diacyl-3-dimethylammonium-propane (DAP). 7. The drug delivery system of a poorly water-soluble drug according to claim 1, wherein the targeting material is at least one selected from the group consisting of bevacizumab, erlotinib, gefitinib, imatinib mesylate, cetuximab, rituximab, trastzumab, folate and RGD. 8. The drug delivery system of a poorly water-soluble drug according to claim 1, wherein the poorly water-soluble drug is at least one selected from the group consisting of poorly water-soluble anticancer agent, antiviral agent, steroidal anti-inflammatory drug, antibiotic, antifungal agent, vitamin, prostacyclin, anti-metabolic agent, mitotic, adrenaline antagonist, antiepileptic drug, anti-anxiety drug, tranquilizer, antidepressant, anesthetic drug, pain killer, anabolic steroid, immunosuppressive agent, and immune-stimulant. 9. The drug delivery system of a poorly water-soluble drug according to claim 1, wherein the poorly water-soluble anticancer agent is at least one selected from the group consisting of taxol, idarubicin, mitoxantrone, paclitaxel, docetaxel, methotrexate, trimetrexate, thioguanine, mercaptopurine, cladrabine, amrubicin, octreotide, gosereline, leuprolide, flutamide, casodex, doxorubicin, 5-fluorouracil, fludarabine, cytarabine, mitomycin-C, styrene maleic acid neocarzinostatin (SMANCS), cisplatin, carboplatin, oxaliplatin, carmustine (BCNU), dacabazine, etoposide, daunomycin, dactinomycin, vinca alkaloid, bleomycin, cyclophosphamide, ifosamide, gemcitabine, pemetrexed, camptothecin, irinotecan, topotecan, chlorambucil and melphalan. 10. The drug delivery system of a poorly water-soluble drug according to claim 1, wherein the particle size of the drug delivery system ranges from 30 to 300 nm. 11. The drug delivery system of a poorly water-soluble drug delivery system of a poorly water-soluble drug according to claim 1 at an amount of 20 to 200 mg/kg. 12. A method of preparing the drug delivery system of poorly water-insoluble drug according to claim 1, comprising dissolving cholesteryl ester, triglyceride, phospholipid, cholesterol, cationic lipid and poorly water-soluble drug in an organic solvent and adding water to prepare a solid nanoparticle which comprises a core lipid part comprising cholesteryl ester and triglyceride and a surface lipid part comprising phospholipid, cholesterol and cationic lipid; a poorly water-soluble drug encapsulated in the core lipid part; binding a polymeric linker to the surface lipid part of nanoparticle through amide bond, and attaching a targeting material to the polymeric linker. 13. The method according to claim 12, wherein boiling point of the organic solvent is lower than melting point of cholesterol ester and lower than boiling point of water.

Details for Patent 10,004,694

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2032-09-12
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2032-09-12
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2032-09-12
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2032-09-12
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2032-09-12